DelveInsight’s ’Renal Tubular Acidosis Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Renal Tubular Acidosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Renal Tubular Acidosis market report provides analysis regarding current treatment practices, emerging drug-like ADV7103 (Advicenne), potential therapies, market share of the individual therapies, historical, current, and forecasted Renal Tubular Acidosis market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Renal Tubular Acidosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan



Study Period: 2017–2030

Renal Tubular Acidosis - Disease Understanding and Treatment Algorithm

Renal Tubular Acidosis Overview

Renal tubular acidosis (RTA) is a disease that occurs when the kidneys fail to excrete acids into the urine, which causes a person’s blood to remain too acidic. The term renal tubular acidosis (RTA) is applied to a group of transport defects in the reabsorption of bicarbonate (HCO3_), the excretion of hydrogen ion (H+), or both. This condition was first described in 1935, confirmed as a renal tubular disorder in 1946, and designated “renal tubular acidosis” in 1951.

RTA defines a class of disorders in which excretion of hydrogen ions or reabsorption of filtered bicarbonate is impaired, leading to a chronic metabolic acidosis with a normal anion gap. Symptoms may vary for different types of distal renal tubular acidosis; some commonly shown symptoms are as follows: confusion or decreased alertness, fatigue, impaired growth in children, increased breathing rate, kidney stones, Nephrocalcinosis (too much calcium deposited in the kidneys), Osteomalacia (softening of the bones) and muscle weakness.

Renal Tubular Acidosis Treatment

This chapter covers the details of conventional and current medical therapies available in the Renal Tubular Acidosis market for the treatment of the condition. It also provides the country-wise Renal Tubular Acidosis treatment guidelines across the United States, Europe, and Japan.

DelveInsight’s Renal Tubular Acidosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Renal Tubular Acidosis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Renal Tubular Acidosis Epidemiology

The Renal Tubular Acidosis epidemiology chapters provide insights about historical and current Renal Tubular Acidosis patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Renal Tubular Acidosis epidemiology is segmented by Total prevalent cases of Renal Tubular Acidosis, Cases of Renal Tubular Acidosis by gender, Cases of Renal Tubular Acidosis by Age, Cases of Distal Renal Tubular Acidosis by Types and Type-specific Renal Tubular Acidosis cases. The report includes a thorough analysis of all segmentations.

In the US, the cases of Renal Tubular Acidosis were 45,601 in 2017. Moreover, the Type-specific cases of Renal Tubular Acidosis were highest among Type 1 (distal RTA) and were reported to be 20,064 in the country.

According to DelveInsight’s analysis, the total prevalent population of Renal Tubular Acidosis in seven major markets was 1,08,679 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).

Among all the seven major markets, the United States accounts for the highest number of Renal Tubular Acidosis cases.

Renal Tubular Acidosis Drug Chapters

The drug chapter segment of the Renal Tubular Acidosis report encloses the detailed analysis of Renal Tubular Acidosis pipeline drug. It also helps understand the Renal Tubular Acidosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The aim is not only to correct the biochemical abnormalities but to fundamentally improve growth in children and to prevent the progression of nephrocalcinosis and the development of chronic renal failure at all ages. The basis of therapy is the continuous administration of appropriate amounts of alkali in the form of either bicarbonate or citrate. The amount of alkali administered should compensate for the urinary loss of HCO3_ plus the amount of acid generated by the catabolism of proteins and the skeletal growth. There is just a single therapy in the pipeline for treating individuals with RTA.

Renal Tubular Acidosis Market Outlook
The Renal Tubular Acidosis market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Renal Tubular Acidosis market size, with USD 6.2 million in 2017, while Spain had the smallest market size of Renal Tubular Acidosis with USD 0.9 million in 2017.
Renal Tubular Acidosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Renal Tubular Acidosis market that are expected to get launched in the market during the study period 2017–2030. The analysis covers Renal Tubular Acidosis market uptake by drugs, patient uptake by therapies, and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Renal Tubular Acidosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Renal Tubular Acidosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Renal Tubular Acidosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Renal Tubular Acidosis collaborations, acquisition and merger, licensing, patent details, and other information for Renal Tubular Acidosis emerging therapies.

Reimbursement Scenario in Renal Tubular Acidosis

Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Renal Tubular Acidosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Renal Tubular Acidosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights

  • In the coming years, the Renal Tubular Acidosis market scenario is expected to alter across the 7MM due to the launch of a better therapy covering the drawbacks of the standard of care.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities



Renal Tubular Acidosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Renal Tubular Acidosis Pipeline Analysis
  • Renal Tubular Acidosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies



Renal Tubular Acidosis Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Renal Tubular Acidosis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake



Renal Tubular Acidosis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers



Key Questions
Market Insights:

  • What was the Renal Tubular Acidosis market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Renal Tubular Acidosis total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Renal Tubular Acidosis market size during the forecast period (2017–2030)?
  • At what CAGR, the Renal Tubular Acidosis market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Renal Tubular Acidosis market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Renal Tubular Acidosis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?



Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of Renal Tubular Acidosis?
  • What is the historical Renal Tubular Acidosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Renal Tubular Acidosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Renal Tubular Acidosis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Renal Tubular Acidosis during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?



Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the Renal Tubular Acidosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Renal Tubular Acidosis in the USA, Europe, and Japan?
  • What is the Renal Tubular Acidosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Renal Tubular Acidosis?
  • How many therapies are developed by each company for Renal Tubular Acidosis treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Renal Tubular Acidosis treatment?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Renal Tubular Acidosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Renal Tubular Acidosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Renal Tubular Acidosis?
  • What are the global historical and forecasted market of Renal Tubular Acidosis?




Reasons To Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Renal Tubular Acidosis market
  • To understand the future market competition in the Renal Tubular Acidosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Renal Tubular Acidosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Renal Tubular Acidosis market
  • To understand the future market competition in the Renal Tubular Acidosis market



Which geography accounted for the largest Renal Tubular Acidosis market size?

The United States accounted for the largest Renal Tubular Acidosis market size.

What is forecasted Renal Tubular Acidosis market size in 2030?

DelveInsight estimates an increase in Renal Tubular Acidosis Market Size during the study period, 2017–2030

What is the present Renal Tubular Acidosis market drivers?

Increasing opportunities and organizational support.

What is the Renal Tubular Acidosis market barriers?

Drawbacks in the standard of care and focus on single disease outcomes are likely to block the market growth.

How many companies are developing drugs for Renal Tubular Acidosis?

Currently, there is only one key pharma player engaged in developing the drug for Renal Tubular Acidosis.

Which are the leading companies in the Renal Tubular Acidosis market?

Key Player- Advicenne

How is epidemiology segmented for Renal Tubular Acidosis?

Prevalent Cases of Renal Tubular Acidosis, Renal Tubular Acidosis cases by Gender, Cases of RTA by Age, Cases of Distal Renal Tubular Acidosis by Types and Type-specific cases of RTA.